BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 36510916)

  • 21. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extensively drug-resistant tuberculosis in california, 1993-2006.
    Banerjee R; Allen J; Westenhouse J; Oh P; Elms W; Desmond E; Nitta A; Royce S; Flood J
    Clin Infect Dis; 2008 Aug; 47(4):450-7. PubMed ID: 18616396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis.
    Kempker RR; Kipiani M; Mirtskhulava V; Tukvadze N; Magee MJ; Blumberg HM
    Emerg Infect Dis; 2015 Jun; 21(6):992-1001. PubMed ID: 25993036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug Resistance Characteristics of
    Wu X; Yang J; Tan G; Liu H; Liu Y; Guo Y; Gao R; Wan B; Yu F
    Front Cell Infect Microbiol; 2019; 9():345. PubMed ID: 31828045
    [No Abstract]   [Full Text] [Related]  

  • 25. Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from São Paulo, Brazil.
    Matsui T; Pinhata JMW; Rabello MCDS; Brandão AP; Ferrazoli L; Leão SC; Viana-Niero C; Oliveira RS
    Mem Inst Oswaldo Cruz; 2020; 115():e200055. PubMed ID: 32401997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcontinental spread and evolution of Mycobacterium tuberculosis W148 European/Russian clade toward extensively drug resistant tuberculosis.
    Merker M; Rasigade JP; Barbier M; Cox H; Feuerriegel S; Kohl TA; Shitikov E; Klaos K; Gaudin C; Antoine R; Diel R; Borrell S; Gagneux S; Nikolayevskyy V; Andres S; Crudu V; Supply P; Niemann S; Wirth T
    Nat Commun; 2022 Aug; 13(1):5105. PubMed ID: 36042200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.
    Diriba G; Alemu A; Yenew B; Tola HH; Gamtesa DF; Mollalign H; Eshetu K; Moga S; Abdella S; Tollera G; Kebede A; Dangisso MH
    Int J Infect Dis; 2023 Jul; 132():50-63. PubMed ID: 37072053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China.
    Yuan X; Zhang T; Kawakami K; Zhu J; Zheng W; Li H; Deng G; Tu S; Liu W
    BMC Infect Dis; 2013 Jul; 13():315. PubMed ID: 23849244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of multidrug resistant tuberculosis.
    Daley CL; Caminero JA
    Semin Respir Crit Care Med; 2013 Feb; 34(1):44-59. PubMed ID: 23460005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A five-year review of prevalence and treatment outcomes of pre-extensively drug-resistant plus additional drug-resistant tuberculosis in the Henan Provincial Tuberculosis Clinical Medicine Research Centre.
    Li Z; Liu F; Chen H; Han Y; You Y; Xie Y; Zhao Y; Tan J; Guo X; Cheng Y; Wang Y; Li J; Cheng M; Xia S; Niu X; Wei L; Wang W
    J Glob Antimicrob Resist; 2022 Dec; 31():328-336. PubMed ID: 36210030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region.
    Porwal C; Kaushik A; Makkar N; Banavaliker JN; Hanif M; Singla R; Bhatnagar AK; Behera D; Pande JN; Singh UB
    PLoS One; 2013; 8(2):e55299. PubMed ID: 23390524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-Genome Sequencing for Resistance Prediction and Transmission Analysis of Mycobacterium tuberculosis Complex Strains from Namibia.
    Claassens M; Dreyer V; Nepolo E; Mokomele Q; van Rooyen G; Ruswa N; Günther G; Niemann S
    Microbiol Spectr; 2022 Oct; 10(5):e0158622. PubMed ID: 36165641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the QuantaMatrix Multiplexed Assay Platform for Molecular Diagnosis of Multidrug- and Extensively Drug-Resistant Tuberculosis Using Clinical Strains Isolated in Myanmar.
    Chang Y; Kim S; Kim Y; Ei PW; Hwang D; Lee J; Chang CL; Lee H
    Ann Lab Med; 2020 Mar; 40(2):142-147. PubMed ID: 31650730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China: 2006 versus 2012.
    Yin QQ; Jiao WW; Li QJ; Xu F; Li JQ; Sun L; Li YJ; Huang HR; Shen AD
    BMC Microbiol; 2016 May; 16():85. PubMed ID: 27176471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis.
    Dowdy DW; van't Hoog A; Shah M; Cobelens F
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):647-54. PubMed ID: 24903933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidrug- and Extensively Drug-Resistant Mycobacterium tuberculosis Beijing Clades, Ukraine, 2015.
    Merker M; Nikolaevskaya E; Kohl TA; Molina-Moya B; Pavlovska O; Brännberg P; Dudnyk A; Stokich V; Barilar I; Marynova I; Filipova T; Prat C; Sjöstedt A; Dominguez J; Rzhepishevska O; Niemann S
    Emerg Infect Dis; 2020 Mar; 26(3):481-490. PubMed ID: 32091369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance.
    Alame-Emane AK; Xu P; Pierre-Audigier C; Cadet-Daniel V; Shen X; Sraouia M; Siawaya JF; Takiff H; Gao Q; Gicquel B
    Int J Tuberc Lung Dis; 2015 Jun; 19(6):679-84. PubMed ID: 25946359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.